Travere Therapeutics (TVTX) Other financing activities (2013 - 2023)

Travere Therapeutics has reported Other financing activities for 10 years, with the latest figure at -$259000.0 in Q4 2023.

• For the quarter ending Q4 2023, Other financing activities rose 97.9% year-over-year to -$259000.0; the trailing twelve-month figure through Sep 2024 stood at -$259000.0 (up 98.08% YoY), and the FY2023 full-year result was -$1.4 million, up 44.25% from the prior year.
• Other financing activities for Q4 2023 stood at -$259000.0, roughly flat from -$260000.0 in the prior quarter.
• The five-year high for Other financing activities was $9.5 million in Q1 2022, with the low at -$12.4 million in Q4 2022.
• Historically, Other financing activities has averaged -$1.0 million across 4 years, with a median of -$259000.0 in 2023.
• The largest YoY upside for Other financing activities was 97.9% in 2023 against a maximum downside of 165.74% in 2023.
• Travere Therapeutics' Other financing activities stood at $772000.0 in 2019, then tumbled by 890.67% to -$6.1 million in 2021, then sank by 102.51% to -$12.4 million in 2022, then soared by 97.9% to -$259000.0 in 2023.
• The last three Other financing activities figures came in at -$259000.0 (Q4 2023), -$260000.0 (Q3 2023), and -$259000.0 (Q2 2023), per Business Quant data.